保留Retzius间隙机器人辅助根治性前列腺癌挽救性手术的早期经验:肿瘤学与功能结局
单术者回顾性分析26例挽救性机器人前列腺切除术患者,其中20例采用保留Retzius间隙入路(sRS-RARP),6例采用标准入路(sRARP),比较围手术期及功能结局。sRS-RARP组手术时间更短、出血更少,即刻、3个月及12个月控尿率均显著优于sRARP组,生化复发率组间无显著差异。提示sRS-RARP在挽救性设置中可行、肿瘤学安全,并可能改善控尿功能。
核心结论
- 早期经验表明,sRS-RARP在挽救性前列腺切除术中可行、肿瘤学安全,并可能较sRARP改善控尿功能。
研究设计与样本
- 单中心回顾性比较研究,纳入2012年1月至2020年5月由单一术者(RM)完成的26例挽救性机器人前列腺切除术患者,其中20例行sRS-RARP,6例行sRARP。
主要发现
- sRS-RARP组与sRARP组术前特征(年龄、种族、PSA水平、Gleason评分)无显著差异,多数患者(69.2%)曾接受原发性外照射放疗。
- 术后中位住院时间1天,中位导尿管留置时间14.0天(IQR 11.5-17),中位生化失败时间7.9年(IQR 6.1-13.4)。
关键数值与推荐
- sRS-RARP组与sRARP组在手术时间、出血量、控尿率及控尿恢复时间上存在显著差异,具体数值如上。
临床怎么用
- 对于放疗后生化复发的选择性患者,sRS-RARP可作为挽救性机器人前列腺切除术的可行术式,可能加快控尿恢复并提高控尿率。
局限性
- 回顾性设计、样本量小(sRARP组仅6例)、单术者经验,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report on feasibility, safety, and continence outcomes using the Retzius-sparing approach in the salvage setting (sRS-RARP). MATERIALS AND METHODS: A total of 26 patients underwent robotic salvage prostatectomy at our institution from January 2012 to May 2020 by a single surgeon (RM). Twenty patients underwent sRS-RARP and 6 underwent the standard approach (sRARP). Pre-, intra-, and postoperative outcomes were compared between these groups with emphasis on continence and oncologic safety. RESULTS: Patients had comparable preoperative characteristics with no significant difference in age, race, prostate-specific antigen level, and Gleason score. Most patients underwent primary external beam radiation therapy (69.2%). Median time to biochemical failure was 7.9 years (IQR 6.1-13.4). sRS-RARP required less console time (141.5 vs 199.5.0 minutes, P = .008) and less blood loss (50.0 mL vs 100.0 mL, P = .045) compared to sRARP. Postoperative course was uneventful with a median hospital stay of 1 day. Median catheterization time was 14.0 days (IQR 11.5-17). Patients undergoing sRS-RARP had better immediate (25.0% vs 0.0%, P < .001), 3 month (80.0% vs 0%, P < .001), and 12 month continence rates (100% vs 44%, P = .0384) compared to sRARP patients. Likewise, median time to continence was significantly shorter for sRS-RARP patients (90.0 vs 270.0 days, P = .0095). Biochemical recurrence rate was 20.0% in the sRS-RARP group and 33.3% in the sRARP group (P = .60). CONCLUSION: Early experience suggests that sRS-RARP is feasible, oncologically safe, and may offer improved continence compared to the sRARP approach.
引用
- Madi R, Sayyid RK, Hiffa A, et al. Early Experience with Salvage Retzius-sparing Robotic-assisted Radical Prostatectomy: Oncologic and Functional Outcomes. Urology. 2021. PMID: 33417926. doi:10.1016/j.urology.2020.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。